Comparative Pharmacology
Head-to-head clinical analysis: MAGNACORT versus PENECORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNACORT versus PENECORT.
MAGNACORT vs PENECORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid receptor agonist; modulates gene transcription to produce anti-inflammatory and immunosuppressive effects.
PENECORT is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression and suppressing inflammation, immune responses, and adrenal function.
5 mg orally once daily for 7 days, then 5 mg orally every other day for 7 days. Alternatively, 1 mg/kg intravenously every 12 hours for 14 days.
2.5-5 mg orally once daily; maximum 10 mg/day. Intramuscular: 20-40 mg every 2-4 weeks.
None Documented
None Documented
3.5 ± 0.8 hours (terminal); prolonged in renal impairment (up to 12 hours in ESRD) and hepatic disease; requires dose adjustment in CrCl <30 mL/min
Terminal elimination half-life: 3-4 hours in adults; prolonged in hepatic impairment (up to 8 hours).
Renal (80% as unchanged drug and metabolites, primarily via glomerular filtration and tubular secretion); biliary/fecal (15%)
Renal: 60-70% as metabolites, 5-10% unchanged; Biliary/fecal: 20-30% as metabolites.
Category C
Category C
Corticosteroid
Corticosteroid